Articles related to MELANOMA

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.

Resistance to immune checkpoint inhibitors is common. In a prior phase Ib study, the combination of talimogene laherparepvec (T-VEC) pembrolizumab demonstrated an encouraging complete response rate and acceptable safety profile in patients with advanced melanoma. In this phase III, randomized, double-blind, multicenter, international study, the combination of T-VEC-pembrolizumab did not statistically improve PFS or OS vs placebo-pembrolizumab. However, T-VEC-pembrolizumab demonstrated a numerical PFS improvement without new safety signals.

A 76-year-old Black woman arrives at the clinic for an evaluation of a slowly increasing bump on her face that she discovered about a year ago, which hasn’t itched, burnt, or caused any other pain. Is it a trichofolliculoma, a hypertrophic scar, basal cell carcinoma, or a cutis osteoma?

Examining data on nearly half a million participants from the NIH-AARP Diet and Health Study revealed that individuals in the highest quintile of total fish intake had a 22% higher risk for malignant melanoma compared to those in the bottom quintile.

A randomized trial showed no significant difference in the rate of invasive melanoma between patients taking daily aspirin and those taking a placebo. There were slightly fewer melanoma events in the aspirin group than in the placebo group — 177 and 189, respectively — but the difference between the groups was not statistically significant (hazard ratio [HR], 0.94; 95% CI, 0.77-1.16; P =.58). Similarly, there were slightly fewer invasive melanoma events in the aspirin group than in the placebo group — 76 and 94, respectively — but the between-group difference was not significant (HR, 0.81; 95% CI, 0.60-1.10; P =.18).